 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Armauer Hansen Research Institute and Ohio State Global One Health |
| Street 1: | Jimma Road |
| Street 2: | |
| City: | Addis Ababa |
| Province: | |
| Post Code: | 1005 |
| Country: | Ethiopia |
| Phone: | +251113483752 |
| Organization Email: | mitku.1@osu.edu |
| Web Site: | http://ahri.gov.et/ |
| Other Online Presence: | http://oia.osu.edu/units/global-one-health-initiative/ |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 530/2023 |
| Organization Type - Primary: | Academic / Research Institution |
| Organization Type - Secondary: | None |
| Organization Description: | |
| Mission To improve the health and wellbeing of the public by generating and delivering scientific evidence, developing and producing new/improved products, equipment, and methods; providing support to the pharmaceutical industry; and serving as a hub for technology transfer and capacity building that increases the country’s sustainable economic, social, and environmental benefits. ARHI was initially established to investigate the pathogenesis and human immune responses to leprosy. However, it undertakes medical research on a wide range of diseases, such as tuberculosis, malaria, antimicrobial resistance, HIV, various cancers, and other non-communicable conditions. The research activities are organized and carried out under seven research directorates. These are: the communicable and non-communicable diseases research directorate (CNCDRD); the clinical trial directorate (CTD), the knowledge management directorate (KMD); the vaccine, diagnostic, and medical devices research and development directorate (VDMDRDD), the traditional and modern medicine Research and Development Directorate (TMMRDD), Pharmaceutical Industry Development Directorate (PIDD) and Pharmaceutical and Biological Product Development Directorate (PBPDD). My interest in tuberculosis stems from a profound commitment to infectious disease research and public health. I am engaged in studying the epidemiology, pathogenesis, and treatment strategies of TB, aiming to develop innovative control measures. My work includes publishing significant research findings and collaborating with global health organizations to enhance TB diagnostics, treatment protocols, and preventative strategies. |
|
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development Technical Assistance |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 51 - 99 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Other partners |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| The Armauer Hansen Research Institute (AHRI) plays a significant role in supporting Ethiopia's national TB control efforts through a variety of initiatives and research programs. AHRI conducts extensive research on tuberculosis (TB), including studies on drug-resistant strains and the development of diagnostic tools and treatment strategies. Located within the All-Africa Leprosy Rehabilitation and Training Hospital (ALERT) campus, AHRI is a major center for TB inpatient and outpatient care, as well as for managing multidrug-resistant TB (MDR-TB) cases?. AHRI is also heavily involved in building research capacity in Ethiopia by aligning its training programs with the priorities outlined in the National Plan for Tuberculosis Research in Ethiopia. This includes providing mentorship and leadership training to Ethiopian scientists and health professionals, thus enhancing the country's ability to conduct robust TB-related research. Additionally, AHRI collaborates with international partners to foster innovation in healthcare and contribute to global TB control efforts?. |
|
Geographical Reach | |
| Which country is your headquarters located in: | Ethiopia |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Ethiopia |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: AHRI engages in advocacy, communications, and social mobilization to enhance TB care delivery. They host events and collaborate with international bodies to raise awareness and promote TB control policies. Drug-Resistant TB: AHRI conducts research and trials on drug-resistant TB, contributing to understanding and managing multi-drug-resistant TB strains in Ethiopia and beyond. They collaborate with global health organizations to develop and implement effective treatment strategies? TB-HIV: The institute is involved in research addressing TB-HIV co-infections, aiming to develop integrated treatment approaches to manage both diseases concurrently, which is critical in regions with high HIV prevalence Laboratory Strengthening: AHRI is involved in strengthening laboratory capacities in Ethiopia, ensuring high-quality diagnostics and research capabilities. This includes training and capacity-building programs to enhance local research competencies? New Diagnostics: The institute is actively developing and evaluating new diagnostic tools for TB to ensure early and accurate detection. They work in partnership with international research bodies to bring innovative diagnostic solutions to the field New TB Drugs: AHRI participates in clinical trials and research projects aimed at discovering and testing new TB drugs. Their collaborations extend to various global health organizations to expedite the development and approval of effective treatments? New TB Vaccines: AHRI is engaged in vaccine research, including the development and testing of new TB vaccines. They collaborate with international vaccine institutes to advance vaccine research and development Fundamental Research: The institute conducts fundamental research on the mycobacterium causing TB, exploring its biology and pathogenesis. This research underpins the development of new diagnostics, drugs, and vaccines. Research: AHRI focuses on training the next generation of researchers through postgraduate programs and international collaborations. They offer training in clinical research, laboratory techniques, and field studies to build local capacity and expertise |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | May 22, 2024 |
| Last updated: | May 23, 2024 |